menu
    • menu

    Company profile for Biohaven Pharmaceuticals

    NEW Drugs in Dev: 18
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Biohaven is engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. The most advanced product candidate from our CGRP receptor antagonist platform is rimegepant. The most advanced product candidate from our glutamate modulation platform is trigriluzole, which we are developing for the treatment of ataxias with an initial focus on spinocerebellar ataxia, or SCA. We have rece...
    Biohaven is engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. The most advanced product candidate from our CGRP receptor antagonist platform is rimegepant. The most advanced product candidate from our glutamate modulation platform is trigriluzole, which we are developing for the treatment of ataxias with an initial focus on spinocerebellar ataxia, or SCA. We have received orphan drug designation from the FDA for trigriluzole in SCA, and we began a Phase 2/3 clinical trial in SCA in December 2016 and expect to report topline results in early 2018.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Biohaven PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Biohaven Pharmaceuticals, Inc 234 Church Street New Haven, CT 06510
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.biohavenpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/biohaven-pharmaceuticals-inc/?originalSubdomain=in
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/biohavenpharma?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASCO GU

    ASCO GU

    Not Confirmed

    envelop Contact Supplier

    ASCO GU

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Biohaven CEO Calls Recent FDA Decisions 'A Systemic Problem'
    Biohaven CEO Calls Recent FDA Decisions 'A Systemic Problem'

    13 Feb 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/its-really-dire-time-patients-biohaven-ceo-says-fda-red-tape-blocking-access-rare-disease

    FIERCE BIOTECH
    13 Feb 2026
    Share Share
    Biohaven Prepares To Challenge Lilly After Tough 2025
    Biohaven Prepares To Challenge Lilly After Tough 2025

    20 Jan 2026

    // BIOSPACE

    https://www.biospace.com/business/jpm26-after-a-tough-2025-biohaven-is-gearing-up-to-challenge-goliath-lilly

    BIOSPACE
    20 Jan 2026
    Share Share
    Biohaven Showcases Advances In Degrader Programs At J.P. Morgan
    Biohaven Showcases Advances In Degrader Programs At J.P. Morgan

    12 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biohaven-highlights-portfolio-progress-positive-early-patient-data-from-priority-degrader-programs-and-anticipated-milestones-at-the-44th-annual-jp-morgan-healthcare-conference-302658655.html

    PR NEWSWIRE
    12 Jan 2026
    Share Share
    Biohaven To Present At J.P. Morgan Healthcare Conference
    Biohaven To Present At J.P. Morgan Healthcare Conference

    07 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biohaven-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-on-january-12-2026-302654353.html

    PR NEWSWIRE
    07 Jan 2026
    Share Share
    Biohaven Updates Phase 2 BHV-7000 Trial in Major Depression
    Biohaven Updates Phase 2 BHV-7000 Trial in Major Depression

    24 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biohaven-provides-update-from-phase-2-proof-of-concept-study-with-bhv-7000-in-major-depressive-disorder-302649251.html

    PR NEWSWIRE
    24 Dec 2025
    Share Share
    Biohaven Shares BHV-1510 Safety Data with Cemiplimab at ESMO 2025
    Biohaven Shares BHV-1510 Safety Data with Cemiplimab at ESMO 2025

    11 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biohaven-presents-clinical-safety-and-efficacy-data-for-bhv-1510-a-next-generation-trop2-antibody-drug-conjugate-in-combination-with-cemiplimab-at-the-2025-european-society-for-medical-oncology-esmo-immuno-oncology-congress-302638503.html

    PR NEWSWIRE
    11 Dec 2025
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search